Sangon Biotech: difference between revisions
Diff·revision 16 → 17·03:08, 1 Aug 2025
Difference between revision 16 and revision 17 of Sangon Biotech. 13 lines changed; the page grew by 1,893 bytes.
| Revision 16 — 19:20, 13 Jul 2025 BlindSampleBrid (talk) state which lines are held in regional stock 9,654 bytes +873 | Revision 17 — 03:08, 1 Aug 2025 BlindSampleBrid (talk) move a stray full stop inside the reference 11,547 bytes +1,893 | ||
|---|---|---|---|
| 74 | The PeptidePedia tally records 751 self-reported submissions to July 2026. Recurring themes are catalogue breadth and the documentary standard of the laboratory-reagent lines, which submissions describe as following the conventions of the reagent trade rather than those of the research-compound trade.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 74 | The PeptidePedia tally records 751 self-reported submissions to July 2026. Recurring themes are catalogue breadth and the documentary standard of the laboratory-reagent lines, which submissions describe as following the conventions of the reagent trade rather than those of the research-compound trade.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| 75 | 75 | ||
| + | 76 | === How this tally should be read === | |
| + | 77 | The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is '''weak evidence''' and is subject to three limitations that apply to every such figure on this wiki: | |
| + | 78 | ||
| + | 79 | * '''Self-selection.''' People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions. | |
| + | 80 | * '''It measures reception, not quality.''' Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly. | |
| + | 81 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | |
| + | 82 | ||
| + | 83 | == Regulatory position and legal status == | |
| + | 84 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | |
| + | 85 | ||
| + | 86 | Material labelled [[Research use only|for research use only]] is outside the regulatory framework that governs medicines. Its identity, purity, sterility and [[Bacterial endotoxin test|endotoxin]] content are not assured by any regulator, and a [[Certificate of analysis|certificate of analysis]] issued by a supplier is a claim by that supplier rather than an independent finding.{{r|ruo,usp1503}} | |
| + | 87 | ||
| 76 | == References == | 88 | == References == |
| 77 | {{reflist}} | 89 | {{reflist}} |
| ⋮ | ⋮ | ||
| 80 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 92 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 81 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 93 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 94 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 82 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 95 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 83 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 96 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |